Women with diabetes, especially African American and Hispanic women, have worse cardiovascular risk factor profiles than men with diabetes do, according to a new report. 

Increased excretion of IgM foretells serious cardiovascular issues. 

This is an exciting week for many of our readers. As you receive this newsletter over 3,000 of the most recognized experts in Diabetes Care, CDE’s, will be gathering in Atlanta for the American Association of Diabetes Educator’s 36th Annual Meeting. This year there is a lot to talk about. …

2nd DPP-4 inhibitor gets FDA Approval Onglyza™ (saxagliptin) a new DPP-4 inhibitor similar to Januvia will give physicians another option in treating their patients with diabetes. See This Week’s Item #1.

New Insulin Patch gets FDA Approval A new mini tubeless insulin infusion patch will go on sale in the U.S.. See this week’s new product information and check out This Week’s Item #4.

Diabetes in Control is the first to present the Solo product information to the diabetes community.   The FDA approved the Solo MicroPump for sale in the US on July 28th, The Solo MicroPump will be the smallest, lightest, most discreet full-featured insulin pump in the market. In addition, it will offer …

Patients with Type 2 diabetes now have a new treatment option: saxagliptin, a dipeptidyl peptidase-4 inhibitor that stimulates the pancreas to create more insulin after meals.

Several risk factors may help identify factors linked to poor outcomes for bariatric surgery, according to the results of a study. 

Obese children are at risk for diabetes and heart disease, according to a report. Children are not only becoming obese, but becoming severely obese, which impacts their overall health says Joseph Skelton, M.D., lead author and director of the Brenner FIT (Families in Training) Program. “These findings reinforce the fact that …

Medingo US, Inc., announced that it will introduce its miniature, tube-free insulin delivery system, the Solo MicroPump, at the American Association of Diabetes Educators Meeting in Atlanta, GA, August 5-8, 2009, Booth 730 . The company received its FDA clearance letter (K090245) on July 28, 2009.